Precision Optics Announces Pricing of $5.1 Million Offering of Common Stock to Fund Business Expansion
20 Fevereiro 2025 - 11:00AM
Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading
designer and manufacturer of advanced optical instruments for the
medical and defense/aerospace industries, today announced that it
has entered into securities purchase agreements with institutional
and accredited investors for the purchase and sale of 1,272,500
shares of the Company's common stock, par value $0.01 per share,
pursuant to a registered direct offering at a purchase price of
$4.00 per share, resulting in gross proceeds of approximately $5.1
million, and expected net proceeds of approximately $5.0 million
after deducting offering expenses. The Company intends to use the
net proceeds from the offering to repay certain indebtedness,
expand its facilities to support expected growth and related
general working capital purposes.
The closing of the offering, which was led by
existing stockholders, is expected to occur on or about February
21, 2025, subject to the satisfaction of customary closing
conditions.
This offering is being made pursuant to an
effective shelf registration statement on Form S-3 (File No.
333-280047) previously filed with the U.S. Securities and Exchange
Commission (the “SEC”) and declared effective on June 14, 2024. A
prospectus supplement describing the terms of the offering will be
filed with the SEC and will be available on the SEC’s website
located at http://www.sec.gov.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Precision Optics
CorporationFounded in 1982, Precision Optics is a
vertically integrated optics company primarily focused on
leveraging its proprietary micro-optics, 3D imaging and digital
imaging technologies to the healthcare and defense/aerospace
industries by providing services ranging from new product concept
through mass manufacture. Utilizing its leading-edge in-house
design, prototype, regulatory and fabrication capabilities as well
as its Ross Optical division's high volume world-wide sourcing,
inspecting and production resources, the Company is able to design
and manufacture next-generation product solutions to the most
challenging customer requirements. Within healthcare, Precision
Optics enables next generation medical device companies around the
world to meet the increasing demands of the surgical community who
require more enhanced and smaller imaging systems for minimally
invasive surgery as well as 3D endoscopy systems to support the
rapid proliferation of surgical robotic systems. In addition to
these next generation applications, Precision Optics has supplied
top tier medical device companies a wide variety of optical
products for decades, including complex endocouplers and
specialized endoscopes. The Company is also leveraging its
technical proficiency in micro-optics to enable leading edge
defense/aerospace applications which require the highest quality
standards and the optimization of size, weight and power. For more
information, please visit www.poci.com.
About Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of U.S. federal securities laws. Such
forward-looking statements include, but are not limited to,
statements regarding the closing of this offering. Any statements
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. In addition, any
statements that refer to projections, forecasts, or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking statements. The words
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intends," "may," "might," "plan," "possible," "potential,"
"predict," "project," "should," "would" and similar expressions may
identify forward-looking statements, but the absence of these words
does not mean that a statement is not forward-looking. The
forward-looking statements contained in this press release are
based on certain assumptions and analyses made by the management of
the Company in light of their respective experience and perception
of historical trends, current conditions, and expected future
developments and their potential effects on the Company as well as
other factors they believe are appropriate in the circumstances.
There can be no assurance that future developments affecting the
Company will be those anticipated. These forward-looking statements
involve a number of risks, uncertainties (some of which are beyond
the control of the parties), or other assumptions that may cause
actual results or performance to be materially different from those
expressed or implied by these forward-looking statements, including
risks that the closing conditions for this offering will not be
achieved, the demand for the Company's products, global supply
chains and economic activity in general and other risks and
uncertainties identified in the Company's filings with the SEC.
Should one or more of these risks or uncertainties materialize or
should any of the assumptions being made prove incorrect, actual
results may vary in material respects from those projected in these
forward-looking statements. We undertake no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, except as may be required
under applicable securities laws.
Company Contact: PRECISION
OPTICS CORPORATION22 East BroadwayGardner, Massachusetts
01440-3338Telephone: 978-630-1800
Investor Contact:LYTHAM
PARTNERS, LLCRobert BlumTelephone:
602-889-9700poci@lythampartners.com
Precision Optics (NASDAQ:POCI)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Precision Optics (NASDAQ:POCI)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025